文献速递眼底病与葡萄膜炎

玻璃体腔注射阿柏西普预防高危眼转化为渗出性年龄相关性黄斑变性的随机临床试验

Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

这项单盲、假注射对照的随机临床试验纳入一眼为中晚期干性AMD且对侧眼为渗出性AMD的高危患者,每季度玻璃体腔注射阿柏西普2mg或假注射,随访24个月。

要点

  • 对侧眼渗出性AMD病史超过2年者,研究眼转化率较低。
  • 安全性与此前玻璃体腔抗VEGF注射研究一致。

核心结论

  • 在高危干性AMD眼中,每季度玻璃体腔注射阿柏西普2mg与假注射相比,24个月转化为渗出性AMD的比例无显著差异。
  • 理解转化为渗出性AMD的机制及可预防该事件的疗法仍是重要的未满足需求。

研究设计与样本

  • 单盲、假注射对照、随机临床试验,在美国4个临床中心进行。
  • 纳入一眼为中期AMD(>10个中等玻璃膜疣[≥63至<125μm]、至少1个大玻璃膜疣[≥125μm]和/或视网膜色素改变)且对侧眼为渗出性AMD的患者。
  • 128例患者入组,127例(阿柏西普组63例,假注射组64例)纳入主要分析;男性68例(53.5%),平均年龄76.5岁(SD 8.1)。
  • 干预为玻璃体腔注射阿柏西普2mg或假注射,每季度一次,持续24个月(1:1随机化)。

主要发现

  • 基线时对侧眼渗出性AMD病史超过2年的患者,研究眼转化率低于对侧眼病史≤2年者。
  • 安全性与此前玻璃体腔抗VEGF注射研究一致。

关键数值与推荐

  • 主要终点为第24个月转化为渗出性AMD的比例,特征为独立 masked 阅读中心评估的荧光素眼底血管造影渗漏和谱域OCT液体所定义的脉络膜新生血管形成。
  • 中期AMD定义:>10个中等玻璃膜疣(≥63至<125μm)、至少1个大玻璃膜疣(≥125μm)和/或视网膜色素改变。

临床怎么用

  • 不推荐每季度阿柏西普2mg用于预防高危干性AMD向渗出性AMD转化。
  • 对侧眼渗出性AMD病史超过2年者转化风险较低,可据此进行风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anti-vascular endothelial growth factor (VEGF) agents may provide a prophylactic effect in high-risk eyes with intermediate dry age-related macular degeneration (AMD) against conversion to exudative AMD (eAMD), lowering the risk of vision loss. OBJECTIVE: To evaluate intravitreal aflibercept injection (IAI) as prophylaxis against the conversion to eAMD in high-risk eyes at 24 months. DESIGN, SETTING, AND PARTICIPANTS: This single-masked, sham-controlled, randomized clinical trial performed at 4 US clinical sites enrolled patients with intermediate AMD in 1 eye (study eye), defined as presence of more than 10 medium drusen (≥63 to <125 μm), at least 1 large druse (≥125 μm), and/or retinal pigmentary changes, and eAMD in the fellow eye. Patients were treated from June 23, 2015, to March 13, 2019. INTERVENTIONS: Intravitreal aflibercept injection (2 mg) or sham quarterly injection for 24 months (1:1 randomization). MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients with conversion to eAMD at month 24 characterized by development of choroidal neovascularization, as assessed by leakage on fluorescein angiography and fluid on spectral-domain optical coherence tomography by an independent masked reading center. RESULTS: Of 128 patients enrolled, 127 (63 in the IAI group and 64 in the sham group) were included in the primary analysis (68 men [53.5%]; mean [SD] age, 76.5 [8.1] years). Baseline demographic and clinical characteristics were balanced between the groups. By month 24, 6 patients (9.5%) in the IAI group and 7 (10.9%) in the sham group developed eAMD (P = .98). Patients with a history of eAMD for longer than 2 years in their fellow eye at baseline showed a lower rate of conversion to eAMD in the study eye compared with those with a history of eAMD for 2 years or less in the fellow eye. Safety was consistent with previous studies involving intravitreal anti-VEGF injections. CONCLUSIONS AND RELEVANCE: In this evaluation of quarterly anti-VEGF exposure as prophylaxis to reduce conversion of eyes with high-risk dry AMD to eAMD, the rates of conversion were not lower in the IAI group compared with the sham treatment group at month 24. Understanding the mechanism of conversion to eAMD and therapies that could prevent this event remains an important unmet need. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02462889.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Heier JS, Brown DM, Shah SP, et al. Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 33734306. doi:10.1001/jamaophthalmol.2021.0221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。